Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype.
- B. Falini, C. Mecucci, +20 authors M. Martelli
- Biology, Medicine
- The New England journal of medicine
- 20 January 2005
Cytoplasmic NPM is a characteristic feature of a large subgroup of patients with AML who have a normal karyotype, NPM gene mutations, and responsiveness to induction chemotherapy. Expand
Nucleophosmin and cancer
The aim of this review is to analyse the role of NPM in cancer, and examine how deregulated NPM activity (either gain or loss of function) can contribute to tumorigenesis. Expand
Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype.
It is demonstrated that NPM1+/FLT3-LM- mutations are an independent predictor for a favorable outcome in AML with normal karyotype. Expand
Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin
- R. Garzon, M. Garofalo, +16 authors B. Falini
- Biology, Medicine
- Proceedings of the National Academy of Sciences
- 11 March 2008
A unique miRNA signature is identified that distinguishes NPMc+ mutated from the cytoplasmic-negative (NPM1 unmutated) cases and includes the up-regulation of miR-10a, miR -10b, several let-7 and miR –29 family members and support a role for miRNAs in the regulation of HOX genes in this leukemia subtype. Expand
Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse.
- F. Aversa, A. Terenzi, +15 authors M. Martelli
- Journal of clinical oncology : official journal…
- 20 May 2005
The mismatched-related transplant emerges as a viable, alternative source of stem cells for acute leukemia patients without matched donors and/or those who urgently need transplantation. Expand
Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features.
NPMc+ AML shows increased frequency in adults and females, wide morphologic spectrum, multilineage involvement, high frequency of FLT3-ITD, CD34 negativity, and a distinct gene-expression profile. Expand
C-kit mutations in core binding factor leukemias.
Positivity for CD117(c-kit) expression is present in 80% of acute myeloblastic leukemia (AML) cases and has been associated with the expression of CD33, a marker of myeloid precursors, and CD13, a myeloids-associated antigen. Expand
Translocations and mutations involving the nucleophosmin (NPM1) gene in lymphomas and leukemias.
The structure and functions of NPM are reviewed, as well as the biological, clinical and pathological features of human hematologic malignancies with NPM1 gene alterations, which indentifies a new category of T/Null lymphomas with distinctive molecular and clinico-pathological features. Expand
Acute myeloid leukemia bearing cytoplasmic nucleophosmin (NPMc+ AML) shows a distinct gene expression profile characterized by up-regulation of genes involved in stem-cell maintenance.
The molecular signature of NPMc+ AML includes up-regulation of several genes putatively involved in the maintenance of a stem-cell phenotype, suggesting that NPM c- AML may derive from a multipotent hematopoietic progenitor. Expand
Nucleophosmin mutations in childhood acute myelogenous leukemia with normal karyotype.
The NPM1 mutation is a frequent abnormality in AML patients without known genetic marker; the mutation may represent a new target to monitor minimal residual disease inAML and a potential candidate for alternative and targeted treatments. Expand